Table 3.
Poisson Mixed Model Explaining Exacerbations in Adults With CF
| Term | Estimate | SE | z Ratio | P Value |
|---|---|---|---|---|
| Intercept | 0.22 | 0.91 | 0.24 | .81 |
| Quarter of y | –0.17 | 0.11 | –1.56 | .12 |
| Male sex | –0.78 | 0.36 | –2.18 | .03 |
| BMI | –0.02 | 0.03 | –0.53 | .60 |
| Patient is taking ETI | –0.43 | 0.33 | –1.29 | .20 |
| FEV1 % predicted | ||||
| 40-69 | –0.42 | 0.51 | –0.81 | .42 |
| 70-89 | –0.69 | 0.52 | –1.32 | .19 |
| > 90 | –1.97 | 0.68 | –2.91 | < .01 |
| During PY | –1.12 | 0.77 | –1.46 | .14 |
| Age group, y | ||||
| 25-34 | –0.31 | 0.42 | –0.73 | .46 |
| 35-44 | –1.16 | 0.57 | –2.05 | .04 |
| 45-54 | –1.52 | 0.66 | –2.30 | .02 |
| 55+ | –0.94 | 0.75 | –1.25 | .21 |
| FEV1 % predicted during PY | ||||
| 40-69 | 0.31 | 0.64 | 0.49 | .63 |
| 70-89 | 0.66 | 0.63 | 1.04 | .30 |
| > 90 | 1.49 | 0.79 | 1.88 | .06 |
| Age during PY, y | ||||
| 25-34 | 0.48 | 0.51 | 0.94 | .35 |
| 35-44 | –0.72 | 1.13 | –0.63 | .53 |
| 45-54 | 0.85 | 0.88 | 0.97 | .33 |
| 55+ | 0.97 | 0.81 | 1.20 | .23 |
Poisson mixed model explaining the number of exacerbations by year adjusted for ETI use, time, sex, BMI, year, lung function cohort, age group, and the interaction between year and lung function cohort and between age group and year. A random slope over time was included for each participant. No significant difference in exacerbation rate was found in the PPY or PY (0.065 /person/y vs 0.054/person/y, respectively; z = 0.41; P = .68). Moderate exacerbations differed by sex, with female patients experiencing 2.2 times as many exacerbations (0.088/person/y; sum = 96) as male patients (0.040/person/y; sum = 38; z = 2.18; P = .03). CF = cystic fibrosis; ETI = elexacaftor/tezacaftor/ivacaftor PPY = prepandemic year; PY = pandemic year.